Arun Jesudian1, Sameer Desale2, Jonathan Julia3, Elizabeth Landry3, Christopher Maxwell3, Bhaskar Kallakury4, Jacqueline Laurin5, Kirti Shetty5. 1. Division of Gastroenterology and Hepatology, Weill Cornell Medical College, United States. 2. MedStar Research Institute, United States. 3. Georgetown University School of Medicine, United States. 4. Department of Pathology, MedStar Georgetown University Hospital, United States. 5. Division of Gastroenterology and Hepatology, Johns Hopkins University, United States.
Abstract
BACKGROUND: The utilization of liver transplantation (LT) is limited by the availability of suitable organs. This study aimed to assess the impact of the donor risk index (DRI) and other donor characteristics on fibrosis progression, graft, and patient survival in hepatitis C virus (HCV)-infected LT recipients. METHODS: HCV-infected LT recipients who had at least 2 post-LT protocol liver biopsy specimens available were included. Hazard ratio for bivariate analysis was computed using Cox proportional hazard regression analysis. RESULTS: Of 312 recipients, 26.6% died over a median follow-up of 58.5 months (95% CI: 46.5-67.3). Fourteen patients underwent re-transplantation. Mean time to graft failure was 84.3 months, median follow-up: 59 months, 95% CI (48.2, 68.3). DRI >1.5 was significantly associated with patient and graft survival (P = 0.04). Of the subset of 104 individuals who underwent histological analysis, 67.3% progressed to ≥F2. On multivariate analysis, significant donor-specific predictors of fibrosis progression were: donor age >50 years and DRI >1.7. CONCLUSIONS: (1) Fibrosis progression in HCV-infected LT recipients is strongly associated with donor characteristics, specifically donor age and DRI. (2) DRI, an objective measure of donor quality, appears to correlate both with rate of histological progression and overall patient/graft survival.
BACKGROUND: The utilization of liver transplantation (LT) is limited by the availability of suitable organs. This study aimed to assess the impact of the donor risk index (DRI) and other donor characteristics on fibrosis progression, graft, and patient survival in hepatitis C virus (HCV)-infected LT recipients. METHODS:HCV-infected LT recipients who had at least 2 post-LT protocol liver biopsy specimens available were included. Hazard ratio for bivariate analysis was computed using Cox proportional hazard regression analysis. RESULTS: Of 312 recipients, 26.6% died over a median follow-up of 58.5 months (95% CI: 46.5-67.3). Fourteen patients underwent re-transplantation. Mean time to graft failure was 84.3 months, median follow-up: 59 months, 95% CI (48.2, 68.3). DRI >1.5 was significantly associated with patient and graft survival (P = 0.04). Of the subset of 104 individuals who underwent histological analysis, 67.3% progressed to ≥F2. On multivariate analysis, significant donor-specific predictors of fibrosis progression were: donor age >50 years and DRI >1.7. CONCLUSIONS: (1) Fibrosis progression in HCV-infected LT recipients is strongly associated with donor characteristics, specifically donor age and DRI. (2) DRI, an objective measure of donor quality, appears to correlate both with rate of histological progression and overall patient/graft survival.
Entities:
Keywords:
AA, African-American; CDA, corrected donor age; CI, confidence interval; CIT, cold ischemic time; DCD, donation after cardiac death; DM, diabetes mellitus; DRI, donor risk index; HBV, hepatitis B virus; HCV, hepatitis C virus; HIV, human immunodeficiency virus; HL, hyperlipidemia; HTN, hypertension; Hepatitis C; LBx, liver biopsy; LT, liver transplantation; MMF, mycophenolate mofetil; OPTN, Organ Procurement and Transplantation Network; OTTR, organ transplant tracking record; REDCap, Research Database Capture; TAC, tacrolimus; UNOS, United Network for Organ Sharing; donor risk index; liver transplantation
Authors: Melisa Dirchwolf; Jennifer L Dodge; Jane Gralla; Kiran M Bambha; Trevor Nydam; Kenneth W Hung; Hugo R Rosen; Sandy Feng; Norah A Terrault; Scott W Biggins Journal: Liver Transpl Date: 2015-08 Impact factor: 5.799
Authors: Tadahiro Uemura; Lucas E Nikkel; Christopher S Hollenbeak; Varun Ramprasad; Eric Schaefer; Zakiyah Kadry Journal: Transpl Int Date: 2012-04-06 Impact factor: 3.782
Authors: Ulf P Neumann; Thomas Berg; Marcus Bahra; Daniel Seehofer; Jan M Langrehr; Ruth Neuhaus; Cornelia Radke; Peter Neuhaus Journal: J Hepatol Date: 2004-11 Impact factor: 25.083
Authors: Victor I Machicao; Hugo Bonatti; Murli Krishna; Bashar A Aqel; Frank J Lukens; Justin H Nguyen; Barry G Rosser; Raj Satyanarayana; Hani P Grewal; Winston R Hewitt; Denise M Harnois; Julia E Crook; Jeffery L Steers; Rolland C Dickson Journal: Transplantation Date: 2004-01-15 Impact factor: 4.939
Authors: Stephen C Rayhill; You Min Wu; Daniel A Katz; Michael D Voigt; Douglas R Labrecque; Patricia A Kirby; Frank A Mitros; Roberto S Kalil; Rachel A Miller; Alan H Stolpen; Warren N Schmidt Journal: Transplantation Date: 2007-08-15 Impact factor: 4.939